Psychiatry research · 2025
Amygdala-targeted neurofeedback for dissociative symptoms in PTSD: Converging evidence from three independent studies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Harmelech Tal, Hendler Talma, Gurevitch Guy, Fine Naomi, Fruchter Eyal, Amital Daniela, Goldental Nadav, Gross Raz, Robinson Matthew A, Lebois Lauren Am, Kaufman Milissa, Tendler Aron
Аннотация
BACKGROUND: Dissociative symptoms occur in 14-30% of PTSD cases and present significant treatment challenges. These symptoms may respond to amygdala-targeted neural regulation training.
METHODS: Secondary analysis of patients with clinically significant dissociative symptoms (CAPS-5 Q29/Q30 >1) from three independent studies: Study 1 - comparison of amygdala neurofeedback + treatment-as-usual (n=14) vs. treatment-as-usual alone (n=7); Study 2 - single-arm neurofeedback study (n=14); Study 3 - comparison of amygdala neurofeedback (n=5) vs. control (n=2).
RESULTS: Large significant within-group improvements in both primary neurofeedback studies (Fine: d=1.82, p<0.001; Fruchter: d=0.85, p=0.007) contrasted with small non-significant effects in control groups. Mixed-effects analysis across all studies showed significant time effects (F=19.8, p<0.001) but non-significant Group × Time interactions. Specificity analysis revealed negligible correlations between dissociation improvements and other PTSD symptom changes (all r<0.17), indicating dissociation-specific rather than general therapeutic effects.
CONCLUSIONS: Convergent evidence from independent studies supports preliminary efficacy of amygdala-targeted neurofeedback for dissociative symptoms. Larger controlled trials with standardized protocols are warranted.
METHODS: Secondary analysis of patients with clinically significant dissociative symptoms (CAPS-5 Q29/Q30 >1) from three independent studies: Study 1 - comparison of amygdala neurofeedback + treatment-as-usual (n=14) vs. treatment-as-usual alone (n=7); Study 2 - single-arm neurofeedback study (n=14); Study 3 - comparison of amygdala neurofeedback (n=5) vs. control (n=2).
RESULTS: Large significant within-group improvements in both primary neurofeedback studies (Fine: d=1.82, p<0.001; Fruchter: d=0.85, p=0.007) contrasted with small non-significant effects in control groups. Mixed-effects analysis across all studies showed significant time effects (F=19.8, p<0.001) but non-significant Group × Time interactions. Specificity analysis revealed negligible correlations between dissociation improvements and other PTSD symptom changes (all r<0.17), indicating dissociation-specific rather than general therapeutic effects.
CONCLUSIONS: Convergent evidence from independent studies supports preliminary efficacy of amygdala-targeted neurofeedback for dissociative symptoms. Larger controlled trials with standardized protocols are warranted.